F. D. Lublin, S. C. Reingold, and J. A. Cohen, Defining the clinical course of multiple sclerosis: the 2013 révisions, Neurology, vol.83, pp.278-286, 2014.

J. F. Kurtzke, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, pp.1444-1452, 1983.

S. J. Pittock, R. L. Mcclelland, and W. T. Mayr, Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study, Ann Neurol, vol.56, pp.303-306, 2004.

J. Correale, M. C. Ysrraelit, and M. P. Fiol, Benign multiple sclerosis: does it exist?, Curr Neurol Neurosci Rep, vol.12, pp.601-609, 2012.

A. L. Sayao, V. Devonshire, and H. Tremlett, Longitudinal follow-up of "benign" multiple sclerosis at 20 years, Neurology, vol.68, pp.496-500, 2007.

B. G. Weinshenker, G. P. Rice, J. H. Noseworthy, W. Carriere, J. Baskerville et al., The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome, Brain, vol.114, pp.1045-1056, 1991.

C. Confavreux and S. Vukusic, Age at disability milestones in multiple sclerosis, Brain, vol.129, pp.595-605, 2006.

M. Debouverie, S. Pittion-vouyovitch, S. Louis, F. Guillemin, and . Group, Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, vol.15, pp.916-921, 2008.

H. El-adssi, M. Debouverie, F. Guillemin, and . Group, Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capturerecapture method, Mult Scler Houndmills Basingstoke Engl, vol.18, pp.1244-1250, 2012.

C. Confavreux, D. A. Compston, O. R. Hommes, W. I. Mcdonald, and A. J. Thompson, EDMUS, a European database for multiple sclerosis, J Neurol Neurosurg Psychiatry, vol.55, pp.671-676, 1992.

C. M. Poser, D. W. Paty, and L. Scheinberg, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, vol.13, pp.227-231, 1983.

W. I. Mcdonald, D. Compston, and G. Edan, Recommended diagnostic criteria for MS: Guidelines from the international panel on the diagnosis of MS, Ann Neurol, vol.50, pp.121-127, 2001.

C. H. Polman, S. C. Reingold, and G. Edan, Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria, Ann Neurol, vol.58, pp.840-846, 2005.

E. Leray, M. Coustans, L. Page, E. Yaouanq, J. Oger et al., Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study, Mult Scler, vol.19, pp.458-465, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00878705

G. S. Ramsaransing, D. Keyser, and J. , Benign course in multiple sclerosis: a review, Acta Neurol Scand, vol.113, pp.359-369, 2006.

M. Debouverie, L. Laforest, E. Van-ganse, F. Guillemin, and . Group, Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients, Mult Scler, vol.15, pp.251-257, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02307061

C. H. Polman, O. Connor, P. W. Havrdova, and E. , A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, pp.899-910, 2006.

L. Kappos, E. W. Radue, O. Connor, and P. , A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, vol.362, pp.387-401, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00617764

M. S. Freedman, Long-term follow-up of clinical trials of multiple sclerosis therapies, Neurology, vol.76, pp.26-34, 2011.

L. D. Jacobs, R. W. Beck, and J. H. Simon, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, N Engl J Med, vol.343, pp.898-904, 2000.

L. Kappos, C. H. Polman, and M. S. Freedman, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, issue.7, pp.1242-1249, 2006.

D. S. Goodin, E. M. Frohman, and G. P. Garmany, Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology, vol.58, pp.169-178, 2002.

S. A. Hawkins and G. V. Mcdonnell, Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors, J Neurol Neurosurg Psychiatry, vol.67, pp.148-152, 1999.

S. B. Glad, H. I. Nyland, and J. H. Aarseth, Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway, Mult Scler, vol.15, pp.942-950, 2009.

R. Zivadinov, D. L. Cookfair, and L. Krupp, Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC), BMC Neurol, vol.16, p.102, 2016.

S. Glad, H. Nyland, and K. M. Myhr, Benign multiple sclerosis, Acta Neurol Scand Suppl, pp.55-57, 2006.

C. Solaro, G. Brichetto, and M. P. Amato, The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study, Neurology, vol.14, pp.919-921, 2004.

J. Correale, I. Peirano, and L. Romano, Benign multiple sclerosis: a new definition of this entity is needed, Mult Scler, vol.18, pp.210-218, 2012.

A. L. Sayao, A. M. Bueno, V. Devonshire, H. Tremlett, U. Ms-clinic et al., The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis, Mult Scler, vol.17, pp.1375-1383, 2011.

L. Kappos, D. Moeri, and E. W. Radue, Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group, Lancet, vol.353, pp.964-969, 1999.

M. Debouverie, C. Lebrun, S. Jeannin, S. Pittion-vouyovitch, T. Roederer et al., More severe disability of North Africans vs Europeans with multiple sclerosis in France, Neurology, vol.68, pp.29-32, 2007.

, les proportions des patients « bénins » atteints de SEP devraient accroître, sous réserve de l'applicabilité de ces thérapeutiques à long terme et en l'absence d'effet indésirable. RÉFÉRENCES BIBLIOGRAPHIQUES

C. M. Poser, D. W. Paty, and L. Scheinberg, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, vol.13, issue.3, pp.227-231, 1983.

W. I. Mcdonald, D. Compston, and G. Edan, Recommended diagnostic criteria for MS: Guidelines from the international panel on the diagnosis of MS, Ann Neurol, vol.50, issue.1, pp.121-127, 2001.

W. A. Sibley, C. R. Bamford, and K. Clark, Clinical viral infections and multiple sclerosis, Lancet, vol.1, issue.8441, pp.1313-1318, 1985.

G. C. Ebers, Environmental factors and multiple sclerosis, Lancet Neurol, vol.7, issue.3, pp.268-77, 2008.

M. Debouverie, S. Pittion-vouyovitch, and L. S. , Natural history of multiple sclerosis in a population-based cohort, Eur J Neurol, vol.15, issue.9, pp.916-937, 2008.

J. F. Kurtzke, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, vol.33, issue.11, pp.1444-52, 1983.

S. B. Glad, J. H. Aarseth, and H. Nyland, Benign multiple sclerosis: a need for a consensus, Acta Neurol Scand Suppl, issue.190, pp.44-50, 2010.

D. Miller, F. Barkhof, and X. Montalban, Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis, Lancet Neurol, vol.4, issue.5, pp.281-289, 2005.

M. Debouverie, L. Laforest, and E. Van-ganse, Earlier disability of the patients followed in Multiple Sclerosis centers compared to outpatients, Mult Scler, vol.15, issue.2, pp.251-258, 2009.

C. Confavreux, S. Vukusic, and P. Adeleine, Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, Brain, vol.126, issue.4, pp.770-82, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00427394

R. Zivadinov, D. L. Cookfair, and L. Krupp, Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC), BMC Neurol, vol.16, p.102, 2016.

M. Filippi, A. Campi, and V. Martinelli, Brain and spinal cord MR in benign multiple sclerosis: a follow-up study, J Neurol Sci, vol.143, issue.1-2, pp.143-152, 1996.

M. Rovaris, F. Barkhof, and M. Calabrese, MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype, Neurology, vol.12, pp.1693-701, 2009.

A. G. Droogan, C. A. Clark, and D. J. Werring, Comparison of multiple sclerosis clinical subgroups using navigated spin echo diffusion-weighted imaging, Magn Reson Imaging, vol.17, issue.5, pp.653-61, 1999.

S. Mesaros, M. Rovaris, and E. Pagani, A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis, Arch Neurol, vol.65, issue.9, pp.1223-1253, 2008.

M. Saresella, A. Gatti, and P. Tortorella, Toll-like receptor 3 differently modulates inflammation in progressive or benign multiple sclerosis, Clin Immunol, vol.150, issue.1, pp.109-129, 2014.

A. Achiron, A. Feldman, and D. Magalashvili, Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis, PLoS One, vol.7, issue.10, p.46871, 2012.

L. Achtnichts, O. Gonen, and D. J. Rigotti, Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration, Eur J Radiol, vol.82, issue.12, pp.848-52, 2013.

M. Calabrese, A. Favaretto, and V. Poretto, Low degree of cortical pathology is associated with benign course of multiple sclerosis, Mult Scler, vol.19, issue.7, pp.904-915, 2013.

L. K. Fisniku, D. T. Chard, and J. S. Jackson, Gray matter atrophy is related to long-term disability in multiple sclerosis, Ann Neurol, vol.64, issue.3, pp.247-54, 2008.

M. Calabrese and P. Gallo, Magnetic resonance evidence of cortical onset of multiple sclerosis, Mult Scler, vol.15, issue.8, pp.933-974, 2009.

R. P. Kinkel, M. Dontchev, and C. Kollman, Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance, Arch Neurol, vol.69, issue.2, pp.183-90, 2012.

L. Kappos, M. S. Freedman, and C. H. Polman, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial, Lancet Neurol, vol.8, issue.11, pp.987-97, 2009.

C. H. Polman, O. Connor, P. W. Havrdova, and E. , A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, N Engl J Med, vol.354, issue.9, pp.899-910, 2006.

E. Leray, M. Coustans, L. Page, and E. , Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study, Mult Scler, vol.19, issue.4, pp.458-65, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00878705

N. D. Chiaravalloti and J. Deluca, Cognitive impairment in multiple sclerosis, Lancet Neurol, vol.7, issue.12, pp.1139-51, 2008.

J. Iriarte, M. L. Subirá, and P. Castro, Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors, Mult Scler, vol.6, issue.2, pp.124-154, 2000.

C. Solaro, G. Brichetto, and M. P. Amato, The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study, Neurology, issue.5, pp.919-940, 2004.

L. D. Jacobs, R. W. Beck, and J. H. Simon, Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, CHAMPS Study Group, vol.343, issue.13, pp.898-904, 2000.

L. Kappos, C. H. Polman, and M. S. Freedman, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes, Neurology, vol.67, issue.7, pp.1242-1249, 2006.

D. S. Goodin, E. M. Frohman, and G. P. Garmany, Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, Neurology, vol.58, issue.2, pp.169-78, 2002.

M. S. Freedman, D. Selchen, and D. L. Arnold, Treatment optimization in MS: Canadian MS Working Group updated recommendations, Can J Neurol Sci, vol.40, issue.3, pp.307-330, 2013.

O. 'brien, M. Lonergan, R. Costelloe, and L. , OAS1: a multiple sclerosis susceptibility gene that influences disease severity, Neurology, vol.3, issue.5, pp.411-419, 2010.

K. P. Wandinger, J. D. Lünemann, and O. Wengert, TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis, Lancet, vol.14, issue.9374, pp.2036-2079, 2003.

D. Miller, F. Barkhof, and X. Montalban, Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis, Lancet Neurol, vol.4, issue.5, pp.281-289, 2005.

O. 'riordan, J. I. Thompson, A. J. Kingsley, and D. P. , The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up, Brain, vol.121, issue.3, p.495, 1998.